查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576773

Gabapentin市场：依产品、给药途径、效力、应用、通路 - 2025-2030 年全球预测

Gabapentin Market by Product (Capsule, Tablet), Route of Administration (Oral, Parenteral), Medication, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年Gabapentin市场价值为22.2亿美元，预计2024年将达到23.2亿美元，预计复合年增长率为4.38%，到2030年将达到30亿美元。

Gabapentin是一种抗惊厥药物，在医药市场上应用广泛，主要用于治疗神经病变疼痛和痉挛。这种需求源于其在神经相关疼痛管理方面的有效性，有助于改善慢性疼痛疾病和癫痫患者的生活品质。Gabapentin的应用超出了这些主要用途，还包括仿单标示外用途，例如治疗焦虑症和不安腿综合征，从而扩大了最终用途的范围。市场洞察表明，神经病变疼痛疾病盛行率的增加和老年人口的增加是关键的成长动力。此外，对非鸦片类疼痛管理解决方案不断增长的需求进一步增加了Gabapentin在市场上的存在。越来越多的专注于扩大Gabapentin丁治疗用途的研究正在为市场创造机会，使製药公司能够投资临床试验以探索更广泛的用途。然而，市场面临来自替代疗法的竞争、潜在副作用、对仿单标示外使用的监管审查以及影响品牌产品的专利到期等挑战。法规环境也是一个限制因素，因为如果非常规用途未经核准，市场扩张可能会受到阻碍。为了克服这些障碍，精准医学和基因分析等创新研究可能会发现具有特定治疗需求的新患者群体并推动有针对性的配方。缓释性和新型联合治疗等递送机制的进步也有可能提高患者的依从性和疗效。此外，与医疗保健提供者伙伴关係以更好地了解患者需求并优化Gabapentin的使用可以进一步推动市场渗透。这就是为什么了解疼痛管理、监管更新和竞争发展的持续发展非常重要。透过技术整合利用资料为公司提供了对患者偏好的洞察，并使行销策略能够提高Gabapentin的市场地位并确保永续成长。该市场的动态本质要求注重战略敏捷性和研究主导的创新，以有效地利用新机会。

主要市场统计
基准年[2023] 22.2亿美元
预测年份 [2024] 23.2亿美元
预测年份 [2030] 30亿美元
复合年增长率（%） 4.38%

市场动态：揭示快速发展的Gabapentin市场的关键市场洞察

Gabapentin市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性疼痛和相关疾病的增加增加了对有效治疗方案的需求
    • 将Gabapentin入多重药物疼痛管理方案以加速临床实务中的采用
    • 旨在改善基本药物取得的政府措施和医疗保健政策
  • 市场限制因素
    • 来自替代疗法、仿冒品和廉价药品的竞争
  • 市场机会
    • 兽医领域对Gabapentin用于宠物和牲畜疼痛管理的需求不断增长
    • Gabapentin作为治疗纤维肌痛和相关慢性疼痛综合症的药物的出现
    • 开发Gabapentin联合治疗提高神经系统疾病的治疗效果
  • 市场挑战
    • 人们越来越担心潜在的副作用和滥用

波特五力：驾驭Gabapentin市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解Gabapentin市场的外部影响

外部宏观环境因素在塑造Gabapentin市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解Gabapentin市场的竞争状况

Gabapentin市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵Gabapentin市场供应商的绩效评估

FPNV定位矩阵是评估Gabapentin市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製Gabapentin市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，Gabapentin市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性疼痛及相关疾病发生率的上升增加了对有效治疗方法的需求
      • 将Gabapentin喷丁纳入多模态疼痛管理方案并促进临床实践中的采用
      • 强调基本药物的可得性和可负担性的政府措施和医疗保健政策
    • 抑制因素
      • 来自替代疗法、假药和廉价药物的竞争
    • 机会
      • 用于宠物和牲畜疼痛管理的兽药对Gabapentin的需求不断增长
      • Gabapentin作为治疗纤维肌痛和相关慢性疼痛综合症的重要药物的出现
      • 开发Gabapentin喷丁联合治疗增强神经系统疾病的治疗效果
    • 任务
      • 对潜在副作用和滥用的担忧增加
  • 市场区隔分析
    • 剂型：胶囊是首选，因为选择方便且容易
    • 用途：广泛用作局部性癫痫发作的辅助性治疗，以稳定神经活动并降低癫痫发作频率。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章Gabapentin市场：副产品

  • 胶囊
  • 锭剂

第七章Gabapentin市场：依给药途径

  • 口服
  • 胃肠外的

第八章Gabapentin药物市场

  • 品牌
  • 非专利的

第九章Gabapentin市场：依应用分类

  • 焦虑
  • 癫痫
  • 神经病变疼痛
  • 不宁腿

第10章Gabapentin市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 美洲Gabapentin市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区Gabapentin市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲Gabapentin市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Stride Pharma 获得美国FDA核准用于神经科治疗Gabapentin
    • Lotus 和 Adalbo 在韩国推出Gabapentin丁缓释製剂
  • 战略分析和建议
Product Code: MRR-3204321AF706

The Gabapentin Market was valued at USD 2.22 billion in 2023, expected to reach USD 2.32 billion in 2024, and is projected to grow at a CAGR of 4.38%, to USD 3.00 billion by 2030.

Gabapentin, an anticonvulsant medication, has a broad scope within the pharmaceutical market, predominantly used to treat neuropathic pain and seizures. Its necessity arises from its effectiveness in managing nerve-related pain conditions, contributing to quality of life improvements for individuals with chronic pain disorders and epilepsy. The application of gabapentin extends beyond these primary uses, also encompassing off-label uses such as managing anxiety disorders and restless leg syndrome, thus widening its end-use scope. Market insights reveal that the growing prevalence of neuropathic pain conditions and the increasing geriatric population are key growth drivers. Additionally, the rise in demand for non-opioid pain management solutions further propels gabapentin's market presence. Opportunities within the market are emerging from the increasing research focused on expanding gabapentin's therapeutic applications, allowing pharmaceutical companies to invest in clinical trials exploring broader uses. However, the market faces challenges, including competition from alternative therapies, potential side effects, regulatory scrutiny concerning off-label uses, and patent expirations impacting branded versions. Regulatory environments also pose limitations, as non-approval for non-traditional uses could stymie market expansion. To navigate these obstacles, innovative areas of research such as precision medicine and genetic profiling could uncover new patient segments with specific therapeutic needs, driving targeted gabapentin formulations. Advancing delivery mechanisms, such as sustained-release formats or novel combination therapies, could also enhance patient compliance and efficacy. Moreover, partnerships with healthcare providers to better understand patient needs and optimize gabapentin use can further market penetration. Therefore, staying attuned to continuous developments in pain management, regulatory updates, and competitive activities is crucial. Harnessing data through technology integration could offer businesses insights into patient preferences, enabling tailored marketing strategies that enhance gabapentin's market position while ensuring sustainable growth. This dynamic nature of the market necessitates strategic agility and a focus on research-driven innovation for leveraging emerging opportunities effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 2.22 billion
Estimated Year [2024] USD 2.32 billion
Forecast Year [2030] USD 3.00 billion
CAGR (%) 4.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gabapentin Market

The Gabapentin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
    • Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
    • Government initiatives and healthcare policies favoring the availability and affordability of essential medications
  • Market Restraints
    • Competition from alternative therapies and counterfeit and cheap-quality drugs
  • Market Opportunities
    • Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
    • Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
    • Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
  • Market Challenges
    • Increasing concerns over potential side effects and misuse

Porter's Five Forces: A Strategic Tool for Navigating the Gabapentin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gabapentin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gabapentin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gabapentin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gabapentin Market

A detailed market share analysis in the Gabapentin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gabapentin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gabapentin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gabapentin Market

A strategic analysis of the Gabapentin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gabapentin Market, highlighting leading vendors and their innovative profiles. These include AVEFLOR, a. s., BD Custom Manufacturing, Capital Resin Corporation, Chemplast Sanmar Limited, Con-Tech International., Custom Manufacturing Corporation, Custom Manufacturing Solutions, Dassault Systemes, Dassault Systemes S.E., East West Manufacturing, LLC, Evonik Industries AG, Formlabs Inc., Ganesh Group of Industries, Grand Prix International PLC, Hexagon AB, Monroe Engineering, LLC, Promega Corporation., Protocase Incorporated, RAS Polska Sp. z o.o., Sartorius AG, SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD, Siemens AG, Thomas Swan & Co. Ltd., and VWR International, LLC..

Market Segmentation & Coverage

This research report categorizes the Gabapentin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Capsule and Tablet.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Medication, market is studied across Branded and Generic.
  • Based on Application, market is studied across Anxiety, Epilepsy, Neuropathic Pain, and Restless Legs Syndrome.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
      • 5.1.1.2. Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
      • 5.1.1.3. Government initiatives and healthcare policies favoring the availability and affordability of essential medications
    • 5.1.2. Restraints
      • 5.1.2.1. Competition from alternative therapies and counterfeit and cheap-quality drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
      • 5.1.3.2. Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
      • 5.1.3.3. Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing concerns over potential side effects and misuse
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Formulation: High preference for capsules due to convenient and straightforward option
    • 5.2.2. Application : Widely utilized as an adjunct therapy for partial seizures to stabilize neuronal activity and reduce seizure frequency
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gabapentin Market, by Product

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Tablet

7. Gabapentin Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Gabapentin Market, by Medication

  • 8.1. Introduction
  • 8.2. Branded
  • 8.3. Generic

9. Gabapentin Market, by Application

  • 9.1. Introduction
  • 9.2. Anxiety
  • 9.3. Epilepsy
  • 9.4. Neuropathic Pain
  • 9.5. Restless Legs Syndrome

10. Gabapentin Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Gabapentin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Gabapentin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Gabapentin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strides Pharma receives USFDA approval for neurology medication Gabapentin
    • 14.3.2. Lotus and Adalvo launch Gabapentin ER in South Korea
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AVEFLOR, a. s.
  • 2. BD Custom Manufacturing
  • 3. Capital Resin Corporation
  • 4. Chemplast Sanmar Limited
  • 5. Con-Tech International.
  • 6. Custom Manufacturing Corporation
  • 7. Custom Manufacturing Solutions
  • 8. Dassault Systemes
  • 9. Dassault Systemes S.E.
  • 10. East West Manufacturing, LLC
  • 11. Evonik Industries AG
  • 12. Formlabs Inc.
  • 13. Ganesh Group of Industries
  • 14. Grand Prix International PLC
  • 15. Hexagon AB
  • 16. Monroe Engineering, LLC
  • 17. Promega Corporation.
  • 18. Protocase Incorporated
  • 19. RAS Polska Sp. z o.o.
  • 20. Sartorius AG
  • 21. SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD
  • 22. Siemens AG
  • 23. Thomas Swan & Co. Ltd.
  • 24. VWR International, LLC.

LIST OF FIGURES

  • FIGURE 1. GABAPENTIN MARKET RESEARCH PROCESS
  • FIGURE 2. GABAPENTIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GABAPENTIN MARKET DYNAMICS
  • TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEGS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023